Found: 137
Select item for more details and to access through your institution.
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 17, p. 9241, doi. 10.3390/ijms25179241
- By:
- Publication type:
- Article
Metastatic extraneural glioblastoma diagnosed with molecular testing.
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. 811, doi. 10.1093/oncolo/oyae115
- By:
- Publication type:
- Article
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 290, doi. 10.1007/s10637-021-01188-1
- By:
- Publication type:
- Article
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 124, doi. 10.1007/s10637-021-01184-5
- By:
- Publication type:
- Article
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1357, doi. 10.1007/s10637-021-01119-0
- By:
- Publication type:
- Article
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 4, p. 1166, doi. 10.1007/s10637-019-00879-0
- By:
- Publication type:
- Article
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 638, doi. 10.1007/s10637-017-0534-0
- By:
- Publication type:
- Article
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 3, p. 416, doi. 10.1007/s10637-017-0513-5
- By:
- Publication type:
- Article
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 4, p. 911, doi. 10.1007/s10637-015-0251-5
- By:
- Publication type:
- Article
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 3, p. 621, doi. 10.1007/s10637-015-0226-6
- By:
- Publication type:
- Article
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 3, p. 700, doi. 10.1007/s10637-015-0238-2
- By:
- Publication type:
- Article
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 177, doi. 10.1007/s10637-014-0173-7
- By:
- Publication type:
- Article
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 215, doi. 10.1007/s10637-014-0176-4
- By:
- Publication type:
- Article
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 465, doi. 10.1007/s10637-013-0051-8
- By:
- Publication type:
- Article
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 2, p. 279, doi. 10.1007/s10637-013-9966-3
- By:
- Publication type:
- Article
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 6, p. 1505, doi. 10.1007/s10637-013-0013-1
- By:
- Publication type:
- Article
Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 7, p. 408, doi. 10.1002/ajh.21423
- By:
- Publication type:
- Article
AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology.
- Published in:
- Cell & Bioscience, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13578-022-00793-8
- By:
- Publication type:
- Article
Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD anderson cancer center experience.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
The Significance of Anemia in Elderly Patients with Cancer.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 1, p. 100
- By:
- Publication type:
- Article
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
- Published in:
- Experimental Hematology & Oncology, 2020, v. 9, n. 1, p. 1, doi. 10.1186/s40164-020-00159-1
- By:
- Publication type:
- Article
Case report: Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1366271
- By:
- Publication type:
- Article
Detection of Richter's Transformation of Chronic Lymphocytic Leukemia by PET/CT.
- Published in:
- Journal of Nuclear Medicine, 2006, v. 47, n. 8, p. 1267
- By:
- Publication type:
- Article
A nonparametric Bayesian basket trial design.
- Published in:
- Biometrical Journal, 2019, v. 61, n. 5, p. 1160, doi. 10.1002/bimj.201700162
- By:
- Publication type:
- Article
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 5, p. 568, doi. 10.1016/j.clml.2013.03.012
- By:
- Publication type:
- Article
Clinical trial design in the era of precision medicine.
- Published in:
- Genome Medicine, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13073-022-01102-1
- By:
- Publication type:
- Article
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211001538
- By:
- Publication type:
- Article
Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 2, p. 266, doi. 10.1038/s41416-023-02280-4
- By:
- Publication type:
- Article
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2002, v. 50, n. 3, p. 237, doi. 10.1007/s00280-002-0479-6
- By:
- Publication type:
- Article
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.
- Published in:
- Oncology, 2017, v. 92, n. 1, p. 14, doi. 10.1159/000449505
- By:
- Publication type:
- Article
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00369-w
- By:
- Publication type:
- Article
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00341-0
- By:
- Publication type:
- Article
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00159-2
- By:
- Publication type:
- Article
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 7, p. 1, doi. 10.1093/jnci/djv098
- By:
- Publication type:
- Article
A decision support framework for genomically informed investigational cancer therapy.
- Published in:
- 2015
- By:
- Publication type:
- journal article
A pilot study of temsirolimus and body composition.
- Published in:
- Journal of Cachexia, Sarcopenia & Muscle, 2013, v. 4, n. 4, p. 259, doi. 10.1007/s13539-013-0113-y
- By:
- Publication type:
- Article